Cargando…

How well are biologic and conventional DMARDs tolerated in psoriatic arthritis: A real world study

Objective: Even though disease-modifying antirheumatic drugs (DMARDs) are well established in routine clinical practice, longitudinal real-world data for their retention and tolerability are sparse, especially in psoriatic arthritis (PsA) patients. Our objective was to describe the characteristics o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jawad, Issrah I., Nisar, Muhammed K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medical Research and Education Association 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176215/ https://www.ncbi.nlm.nih.gov/pubmed/35156631 http://dx.doi.org/10.5152/eurjrheum.2021.21027

Ejemplares similares

Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
por: Bhushan, Vandana, et al.
Publicado: (2021)

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
por: Coates, Laura C, et al.
Publicado: (2017)

Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis
por: G.S. Saad, Carla, et al.
Publicado: (2023)

Real World Experience of Disease Activity in Patients With Rheumatoid Arthritis and Response to Treatment With Varios Biologic DMARDs
por: Boyadzhieva, Vladimira, et al.
Publicado: (2018)

Delayed conventional DMARDs therapy is effective in Rheumatoid Arthritis
por: Ahsan, Tasnim, et al.
Publicado: (2017)

Effects of bDMARDs on quality of life in patients with psoriatic arthritis: meta-analysis
por: Lu, Yuqiong, et al.
Publicado: (2022)

The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study
por: An, Yuan, et al.
Publicado: (2016)

Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis
por: Hagberg, Katrina Wilcox, et al.
Publicado: (2020)

Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis
por: Holdsworth, Elizabeth A., et al.
Publicado: (2021)

First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine
por: Jacobs, Marleen E, et al.
Publicado: (2020)

Evaluation of the Synovial Effects of Biological and Targeted Synthetic DMARDs in Patients with Psoriatic Arthritis: A Systematic Literature Review and Meta-Analysis
por: Ciliento, Maria Sofia, et al.
Publicado: (2023)

Real-world comparative effectiveness of bDMARDs and JAK inhibitors in elderly patients with rheumatoid arthritis
por: Temmoku, Jumpei, et al.
Publicado: (2022)

The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice
por: Roberts, Lynden, et al.
Publicado: (2017)

Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
por: Gashi, Afrim A., et al.
Publicado: (2014)

Real-world burden of comorbidities in US patients with psoriatic arthritis
por: Shah, Kamal, et al.
Publicado: (2017)

DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis
por: Wang, Susan Siyu, et al.
Publicado: (2023)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

Real‐World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2023)

Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial
por: Wells, Alvin F, et al.
Publicado: (2018)

Medication persistence for psoriatic arthritis in a Brazilian real-world setting
por: Ribeiro da Silva, Michael Ruberson, et al.
Publicado: (2019)

Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis
por: Elliott, Ashley, et al.
Publicado: (2019)

Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis
por: Alegre-Sancho, Juan José, et al.
Publicado: (2023)

Biologic DMARDs and targeted synthetic DMARDs and the risk of all-cause mortality in rheumatoid arthritis: A systematic review and meta-analysis
por: Pang, Mengduan, et al.
Publicado: (2022)

Ultrasound shows swollen joints are the better proxy for synovitis than tender joints in DMARD-naïve early psoriatic arthritis
por: Dubash, Sayam R, et al.
Publicado: (2021)

The CHRONOS Real-World Evidence of Biologic Treatments in Psoriatic Arthritis in Italy: A Post Hoc Gender Analysis
por: Colombo, Delia, et al.
Publicado: (2022)

Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs
por: Strangfeld, A, et al.
Publicado: (2017)

Using real-world data to dynamically predict flares during tapering of biological DMARDs in rheumatoid arthritis: development, validation, and potential impact of prediction-aided decisions
por: van der Leeuw, Matthijs S., et al.
Publicado: (2022)

COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
por: Tsai, Jih-Jin, et al.
Publicado: (2023)

Real-world treatment persistence in patients with rheumatoid arthritis initiating DMARDs in Germany—a health insurance claims data analysis
por: Fiehn, Christoph, et al.
Publicado: (2023)

Analysis of the Pharmacoutilization of Biological Drugs in Psoriatic Arthritis Patients: A Real-World Retrospective Study Among an Italian Population
por: Perrone, Valentina, et al.
Publicado: (2022)

A real-world economic analysis of biologic therapies for psoriatic arthritis in Italy: results of the CHRONOS observational longitudinal study
por: Zagni, Emanuela, et al.
Publicado: (2022)

Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study
por: Christensen, Ingrid Egeland, et al.
Publicado: (2022)

Real-world evidence of biologic treatments in psoriatic arthritis in Italy: results of the CHRONOS (EffeCtiveness of biologic treatments for psoriatic artHRitis in Italy: an ObservatioNal lOngitudinal Study of real-life clinical practice) observational longitudinal study
por: Colombo, Delia, et al.
Publicado: (2022)

Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting
por: Liang, Huifang, et al.
Publicado: (2019)

Real Life Efficacy and Safety of Secukinumab in Biologic-Experienced Patients With Psoriatic Arthritis
por: Klavdianou, Kalliopi, et al.
Publicado: (2020)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

Altered Bone Biology in Psoriatic Arthritis
por: Rahimi, Homaira, et al.
Publicado: (2012)

Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real‐world evidence in Japan
por: Fujita, Hideki, et al.
Publicado: (2020)

The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials
por: Denis, Agathe, et al.
Publicado: (2023)

Discovering adverse drug events combining spontaneous reports with electronic medical records: a case study of conventional DMARDs and biologics for rheumatoid arthritis
por: Wang, Liwei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_d0mrhv39rlhridthmbkjrjo5eg